Catalent and Cevec team-up to offer protein CDMO services

- Last updated on GMT

Catalent and Cevec's new protein CDMO services
Catalent and Cevec Pharmaceuticals have joined forces to offer cell line development and manufacturing services to biotechs.

The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.

The deal follows a joint-study for complex protein production, which saw “record”​ yields of non-antibody proteins produced in a human expression system.

In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative  proprietary technologies.”

Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers